Study of Adaptive Radiotherapy for High-grade Glioma Based on Interfraction MRI

NCT06201351 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2024-01-11

No results posted yet for this study

Summary

The changes of target and organs at risk in patients with high-grade glioma during concurrent chemoradiotherapy were evaluated by MRI image between radiotherapy fractions.

Conditions

  • High-grade Glioma

Interventions

DEVICE

adaptive radiotherapy

MRI was performed and adaptive radiotherapy was administered at farction10 and fraction 20 during radiotherapy.

Sponsors & Collaborators

  • West China Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-01
Primary Completion
2025-12-01
Completion
2026-09-30
FDA Device
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06201351 on ClinicalTrials.gov